Predictive modeling of health care costs: Do cardiovascular risk markers improve prediction?

European Journal of Preventive Cardiology

Volumn 17, Issue 3, 2010, Pages 355-362

  Baumeister, Sebastian E ^a,b   Dörr, Marcus ^c   Radke, Dörte ^b   Nauck, Matthias ^d   John, Ulrich ^a   Marschall, Paul ^a   Fleßa, Steffen ^a   Schmidt, Carsten Oliver ^b   Alte, Dietrich ^b   Völzke, Henry ^b  

^a Institute of Epidemiology   (United States)

^b Institute for Community Medicine   (United States)

^c UNIVERSITY OF GREIFSWALD   (Germany)

^d Department of Internal Medicine B Cardiology ^*  (United States)

Author keywords

cardiovascular diseases; health care costs; markers; risk factors

Indexed keywords

ALBUMIN; ALCOHOL DERIVATIVE; APOLIPOPROTEIN A; APOLIPOPROTEIN B; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; FIBRINOGEN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTERIAL WALL THICKNESS; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; EDUCATIONAL STATUS; FEMALE; FIBRINOGEN BLOOD LEVEL; GERMANY; GLOMERULUS FILTRATION RATE; HEALTH CARE COST; HEALTH INSURANCE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INCOME; INTERVIEW; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; SEX; SMOKING; STATISTICAL MODEL; WAIST CIRCUMFERENCE; AGE; CARDIOVASCULAR DISEASES; CHI SQUARE DISTRIBUTION; ECONOMICS; FORECASTING; HEALTH STATUS INDICATOR; INSURANCE; MIDDLE AGED; PROSPECTIVE STUDY; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; TIME; TRENDS; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; EDUCATIONAL STATUS; FEMALE; FORECASTING; GERMANY; HEALTH CARE COSTS; HEALTH STATUS INDICATORS; HUMANS; INCOME; INSURANCE COVERAGE; INSURANCE, HEALTH; LOGISTIC MODELS; MALE; MIDDLE AGED; MODELS, ECONOMIC; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; TIME FACTORS;

EID: 77954014250     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/HJR.0b013e328333a0b7     Document Type: Article

References (38)

1. Van de Ven WPM, Ellis RP. Risk adjustment in competitive health plan markets. In: Culyer AJ, Newhouse JP, editors. Handbook of health economics. San Diego, CA: Elsevier; 2000. pp. 755–845.
2. Andersen RM. Revisiting the behavorial model and access to medical care: does it matter? Journal of Health and Behavior 1995; 36: 1–10.
3. Charlson ME, Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM, Hollenberg JP. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol 2008; 61: 1234–1240.
4. Fleishman JA, Cohen JW, Manning WG, Kosinski M. Using the SF-12 health status measure to improve predictions of medical expenditures. Med Care 2006; 44: I54–63.
5. Hornbrook MC, Goodman MJ. Chronic disease, functional health status, and demographics: a multi-dimensional approach to risk adjustment. Health Serv Res 1996; 31: 283–307.
6. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008; 358: 2107–2116.
7. Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005; 294: 1799–1809.
8. Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007; 298: 776–785.
9. Meisinger C, Doring A, Lowel H. Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population. Eur Heart J 2006; 27: 1245–1250.
10. Hillege HL, Fidler V, Diercks GF, van Gilst W.H., de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777–1782.
11. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355: 2631–2639.
12. Folsom AR, Chambless LE, Ballantyne CM, Coresh J, Heiss G, Wu KK, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med 2006; 166: 1368–1373.
13. Barr EL, Boyko EJ, Zimmet PZ, Wolfe R, Tonkin AM, Shaw JE. Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian diabetes, obesity, and lifestyle (AusDiab) study. Diabetologia 2009; 52: 415–424.
14. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007; 297: 611–619.
15. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007; 115: 459–467.
16. De Lemos JA, Lloyd-Jones DM. Multiple biomarker panels for cardiovascular risk assessment. N Engl J Med 2008; 358: 2172–2174.
17. John U, Greiner B, Hensel E, Ludemann J, Piek M, Sauer S, et al. Study of Health In Pomerania (SHIP): a health examination survey in an east German region: objectives and design. Soz Praventivmed 2001; 46: 186–194.
18. Luepker RV, Evans A, McKeigue P, Reddy KS. Cardiovascular survey methods. Geneva: WHO; 2004.
19. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440–1463.
20. Graf von der Schulenburg JM, Greiner W, Jost F, Klusen N, Kubin M, Leidl R, et al. German Recommendations on Health Economic Evaluation: Third and Updated Version of the Hanover Consensus, Value Health, in print.
21. Krauth C, Hessel F, Hansmeier T, Wasem J, Seitz R, Schweikert B. Empirische Bewertungssätze in der gesundheitsökonomischen evaluation - Ein Vorschlag der AG Methoden der gesundheitsökonomischen evaluation [empirical standard costs for health economic evaluation in Germany - a proposal by the working group methods in health economic evaluation]. Gesundheitswesen 2005; 67: 736–746.
22. Luedemann J, Schminke U, Berger K, Piek M, Willich SN, Doring A, et al. Association between behavior-dependent cardiovascular risk factors and asymptomatic carotid atherosclerosis in a general population. Stroke 2002; 33: 2929–2935.
23. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247–254.
24. Manning WG, Basu A, Mullahy J. Generalized modeling approaches to risk adjustment of skewed outcomes data. J Health Econ 2005; 24: 465–488.
25. Singer JD, Willet JB. Applied longitudinal data analysis. New York: Oxford University Press; 2003.
26. Long JS, Freese J. Regression models for categorical dependent variables using Stata. College Station. Texas: Stata Press Publication; 2006.
27. Fishman PA, Goodman MJ, Hornbrook MC, Meenan RT, Bachman DJ, O'Keeffe Rosetti MC. Risk adjustment using automated ambulatory pharmacy data: the RxRisk model. Med Care 2003; 41: 84–99.
28. Zheng B, Agresti A. Summarizing the predictive power of a generalized linear model. Stat Med 2000; 19: 1771–1781.
29. Powers CA, Meyer CM, Roebuck MC, Vaziri B. Predictive modeling of total healthcare costs using pharmacy claims data: a comparison of alternative econometric cost modeling techniques. Med Care 2005; 43: 1065–1072.
30. Baumeister SE, Meyer C, Carreon D, Freyer J, Rumpf HJ, Hapke U, et al. Alcohol consumption and health-services utilization in Germany. J Stud Alcohol 2006; 67: 429–435.
31. Baumeister SE, Schumann A, Meyer C, John U, Volzke H, Alte D. Effects of smoking cessation on health care use: is elevated risk of hospitalization among former smokers attributable to smoking-related morbidity? Drug Alcohol Depend 2007; 88: 197–203.
32. Pronk NP, Goodman MJ, O'Connor PJ, Martinson BC. Relationship between modifiable health risks and short-term health care charges. JAMA 1999; 282: 2235–2239.
33. Natarajan S, Nietert PJ. Hypertension, diabetes, hypercholesterolemia, and their combinations increased health care utilization and decreased health status. J Clin Epidemiol 2004; 57: 954–961.
34. Meyer A, Bunzemeier H, Hausberg M, Walter M, Roeder N, Breithardt G, Reinecke H. Impact of different stages of chronic kidney disease on in-hospital costs in patients with coronary heart disease. Nephrol Dial Transplant 2008; 23: 1955–1960.
35. Smith DH, Gullion CM, Nichols G, Keith DS, Brown JB. Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population. J Am Soc Nephrol 2004; 15: 1300–1306.
36. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105–1187.
37. Gilmer TP, O'Connor PJ, Manning WG, Rush WA. The cost to health plans of poor glycemic control. Diabetes Care 1997; 20: 1847–1853.
38. Newhouse JP, Manning WG, Keeler EB, Sloss EM. Adjusting capitation rates using objective health measures and prior utilization. Health Care Financ Rev 1989; 10: 41–54.